J Korean Ophthalmol Soc.  2020 Sep;61(9):1065-1071. 10.3341/jkos.2020.61.9.1065.

Clinical Characteristics of Allergy to a Brinzolamide 1.0%/Brimonidine 0.2% Fixed Combination in Korean Glaucoma Patients

Affiliations
  • 1Department of Ophthalmology, Kyung Hee University Hospital, Kyung Hee University College of Medicine , Seoul, Korea
  • 2Department of Ophthalmology, Chung-Ang University Hospital, Chung-Ang University College of Medicine , Seoul, Korea

Abstract

Purpose
We describe the clinical aspects of allergy to a brinzolamide 1.0%/brimonidine 0.2% fixed combination (BBFC) in Korean patients with glaucoma.
Methods
The medical records of 117 glaucoma patients treated with BBFC were retrospectively analyzed in terms of sex, age, glaucoma type, follow-up period after prescription of eyedrops, number of eyedrop preparations used, allergy onset, and clinical characteristics.
Results
The incidence of ocular allergy during BBFC use was 12.8%. Allergy developed after an average of 8.58 months (range, 0.93-25.80 months); half of all allergies were evident within the first 5 months. The most common type of allergy was follicular conjunctivitis (53.4%), followed by papillary conjunctivitis and blepharoconjunctivitis. Systemic side-effects and eye discomfort (0.09%) were largely confined to non-allergic patients.
Conclusions
An understanding of the clinical pattern of BBFC allergy in Korean glaucoma patients could facilitate treatment compliance and patients’ education.

Keyword

Allergy; Brinzolamide 1.0%/Brimonidine 0.2% Fixed Combination (BBFC); Glaucoma
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr